Supernus Pharmaceuticals, Inc. (SUPN)

NASDAQ | Biotech | Central Nervous System pharmaceuticals
Free
No email, no account, no signup.
Pulling latest news for Supernus Pharmaceuticals, Inc.…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NASDAQ
Type
Biotech
Sector
Central Nervous System pharmaceuticals
Market Cap
$3.0B
We're already tracking Supernus Pharmaceuticals, Inc. — here are the latest events we've registered

Recent News

  • In February 2025, the FDA approved ONAPGO for the treatment of Parkinson's disease, followed by a commercial launch in April 2025. The company also reported significant revenue growth from its ADHD medication Qelbree in its 2025 financial results.
Want to know how this news affects Supernus Pharmaceuticals, Inc.? Order the analysis.
Order analysis – $4.99

What you get

A complete express analysis — not just a signal. Delivered as a webpage in your account.

  • Signal: BUY / HOLD / SELL — with clear reasoning
  • Sentiment score 1–10 based on news, reports, and market data
  • Risk score 1–10 (dilution, jurisdiction, execution)
  • Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
  • Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
  • Upcoming catalysts with dates
  • Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Supernus Pharmaceuticals, Inc. will be delivered in the same format.
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
Supernus Pharmaceuticals, Inc. (SUPN)
Fresh analysis on demand
Order analysis – $4.99
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.